郑重声明:斯道资本从没有通过微信、APP、网站或任何其他渠道以斯道资本名义进行任何此类活动,也没有授权任何实体或个人以斯道资本名义进行任何此类活动。斯道资本进一步声明其从不对外集资或募资,也不直接或间接销售任何投资理财产品,更不接受个人投资。

Shinobi announced their $51M Series A funding
Shinobi Therapeutics, company developing new class of immune evasive iPS-T cell therapies, announced their launch and $51M Series A funding.

Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS-T cell therapies, announced their launch and $51M Series A funding.

Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, MD, at University of California, San Francisco.

 

To learn more about the company and its unique Katana platform click the link below

https://www.prnewswire.com/news-releases/shinobi-therapeutics-launches-with-completion-of-51m-series-a-to-advance-hypoimmune-ips-t-cell-therapy-platform-302012188.html?tc=eml_cleartimeLearn more at: www.shinobitx.com

分享

The information on these pages is intended solely for the benefit of entrepreneurs and businesses seeking venture capital investment. Eight Roads does not offer and is not offering to provide investment advisory services nor is it offering to engage in any transactions in securities.